Pfizer Withheld Crucial Data In Lipitor Patent Filing, Ranbaxy Claims

Law360, New York (November 23, 2004, 12:00 AM EST) -- Pfizer Inc. withheld crucial scientific data that might have influenced the patent review board's decision to grant the drug maker a second patent for Lipitor, attorneys for Indian generics maker Ranbaxy Laboratories Ltd. argued at the opening of the closely watched trial over patent rights to the blockbuster anti-cholesterol drug.

“Ranbaxy does not make this challenge wildly. We realize it is a serious charge,” said Darrell Olson, of the intellectual-property specialty firm Knobbe, Martens, Olson & Bear LLP of Irvine California, representing Ranbaxy.

“Pfizer violated its...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.